Detalles de la búsqueda
1.
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Lancet Oncol
; 25(4): 439-454, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38547891
2.
Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.
Am J Physiol Renal Physiol
; 307(5): F560-70, 2014 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24920756
3.
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Nat Med
; 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38745009
4.
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.
Sci Rep
; 14(1): 12129, 2024 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38802399
5.
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.
J Transl Med
; 11: 75, 2013 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-23521917
6.
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
J Clin Oncol
; 41(31): 4852-4863, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37694347
7.
Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy.
Arterioscler Thromb Vasc Biol
; 28(3): 562-7, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18174457
8.
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.
Arterioscler Thromb Vasc Biol
; 26(12): 2763-8, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17008591
9.
Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke.
Stroke
; 36(11): 2346-50, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16239632
10.
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
J Am Coll Cardiol
; 43(5): 854-7, 2004 Mar 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-14998629
11.
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
EBioMedicine
; 2(3): 264-71, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26137564
12.
Responsiveness to cetuximab without mutations in EGFR.
N Engl J Med
; 353(2): 208-9, 2005 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-16014894
13.
Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
Anticancer Res
; 32(7): 2399-406, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22753696
14.
Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop.
Pharmacogenomics
; 10(1): 127-36, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19102722
15.
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
J Clin Oncol
; 24(30): 4914-21, 2006 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-17050875
16.
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
J Natl Cancer Inst
; 97(16): 1185-94, 2005 Aug 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-16106023
Resultados
1 -
16
de 16
1
Próxima >
>>